KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Aquestive Therapeutics (AQST) Other Gross PP&E Adjustments (2017 - 2025)

Historic Other Gross PP&E Adjustments for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $42.6 million.

  • Aquestive Therapeutics' Other Gross PP&E Adjustments rose 279.45% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.6 million, marking a year-over-year increase of 279.45%. This contributed to the annual value of $40.3 million for FY2024, which is 136.57% up from last year.
  • Aquestive Therapeutics' Other Gross PP&E Adjustments amounted to $42.6 million in Q3 2025, which was up 279.45% from $41.8 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Other Gross PP&E Adjustments registered a high of $43.4 million during Q3 2022, and its lowest value of $39.1 million during Q4 2022.
  • In the last 5 years, Aquestive Therapeutics' Other Gross PP&E Adjustments had a median value of $41.2 million in 2023 and averaged $41.2 million.
  • In the last 5 years, Aquestive Therapeutics' Other Gross PP&E Adjustments tumbled by 704.51% in 2021 and then surged by 573.83% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Other Gross PP&E Adjustments (Quarter) stood at $40.5 million in 2021, then fell by 3.41% to $39.1 million in 2022, then rose by 1.73% to $39.8 million in 2023, then increased by 1.37% to $40.3 million in 2024, then rose by 5.69% to $42.6 million in 2025.
  • Its last three reported values are $42.6 million in Q3 2025, $41.8 million for Q2 2025, and $42.0 million during Q1 2025.